Airflow limitation or static hyperinflation: which is more closely related to dyspnea with activities of daily living in patients with COPD?

Respiratory Research

Toru Oga²  Takashi Nishimura³  Maya Yasui³  Koichi Nishimura¹ 

[1] Department of Respiratory Medicine, Rakuwakai Otowa Hospital, Kyoto, Japan;Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan;Kyoto-Katsura Hospital, Kyoto, Japan

关键词: Baseline Dyspnea Index;    Dyspnea;    Hyperinflation;    Airflow limitation;    Chronic obstructive pulmonary disease;   

Others  :  796787
DOI  :  10.1186/1465-9921-12-135

 received in 2011-06-30, accepted in 2011-10-11,  发布年份 2011

【 摘 要 】

Background

Dyspnea while performing the activities of daily living has been suggested to be a better measurement than peak dyspnea during exercise. Furthermore, the inspiratory capacity (IC) has been shown to be more closely related to exercise tolerance and dyspnea than the FEV₁, because dynamic hyperinflation is the main cause of shortness of breath in patients with COPD. However, breathlessness during exercise is measured in most studies to evaluate this relationship.

Purpose

To evaluate the correlation between breathlessness during daily activities and airflow limitation or static hyperinflation in COPD.

Methods

We examined 167 consecutive outpatients with stable COPD. The Baseline Dyspnea Index (BDI) was used to evaluate dyspnea with activities of daily living. The relationship between the BDI score and the clinical measurements of pulmonary function was then investigated.

Results

The Spearman rank correlation coefficients (Rs) between the BDI score and the FEV₁(L), FEV₁(%pred) and FEV₁/FVC were 0.60, 0.56 and 0.56, respectively. On the other hand, the BDI score also correlated with the IC, IC/predicted total lung capacity (TLC) and IC/TLC (Rs = 0.45, 0.46 and 0.47, respectively). Although all of the relationships studied were strongly correlated, the correlation coefficients were better between dyspnea and airflow limitation than between dyspnea and static hyperinflation. In stepwise multiple regression analyses, the BDI score was most significantly explained by the FEV₁ (R² = 26.2%) and the diffusion capacity for carbon monoxide (R² = 14.4%) (Cumulative R² = 40.6%). Static hyperinflation was not a significant factor for clinical dyspnea on the stepwise multiple regression analysis.

Conclusion

Both static hyperinflation and airflow limitation contributed greatly to dyspnea in COPD patients.

【 授权许可】

   
2011 Nishimura et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]O'Donnell DE, Laveneziana P: The clinical importance of dynamic lung hyperinflation in COPD. COPD 2006, 3(4):219-232.
• [2]O'Donnell DE, Laveneziana P: Dyspnea and activity limitation in COPD: mechanical factors. COPD 2007, 4(3):225-236.
• [3]O'Donnell DE, Webb KA: The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol 2008, 105(2):753-755. discussion 755-757
• [4]O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004, 23(6):832-840.
• [5]O'Donnell DE, Lam M, Webb KA: Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158(5 Pt 1):1557-1565.
• [6]O'Donnell DE, Lam M, Webb KA: Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160(2):542-549.
• [7]O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K: Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006, 130(3):647-656.
• [8]O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA: Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004, 24(1):86-94.
• [9]Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR: Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 171(6):591-597.
• [10]Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T: Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158(4):1185-1189.
• [11]Oga T, Nishimura K, Tsukino M, Hajiro T, Mishima M: Dyspnoea with activities of daily living versus peak dyspnoea during exercise in male patients with COPD. Respir Med 2006, 100(6):965-971.
• [12]Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P: Standardisation of spirometry. Eur Respir J 2005, 26(2):319-338.
• [13]Diseases JSoC: The predicted values of pulmonary function testing and artrial blood gas in Japanese [in Japanese]. Jpn J Thorac Dis 2001, 39(5):appendix.
• [14]Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997, 350(9088):1349-1353.
• [15]Mahler DA, Weinberg DH, Wells CK, Feinstein AR: The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85(6):751-758.
• [16]Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T: Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(3 Pt 1):785-790.
• [17]Murariu C, Ghezzo H, Milic-Emili J, Gautier H: Exercise limitation in obstructive lung disease. Chest 1998, 114(4):965-968.
• [18]Calverley PM: Dynamic hyperinflation: is it worth measuring? Proc Am Thorac Soc 2006, 3(3):239-244.
• [19]Eakin EG, Kaplan RM, Ries AL: Measurement of dyspnoea in chronic obstructive pulmonary disease. Qual Life Res 1993, 2(3):181-191.
• [20]Chhabra SK, Gupta AK, Khuma MZ: Evaluation of three scales of dyspnea in chronic obstructive pulmonary disease. Ann Thorac Med 2009, 4(3):128-132.
• [21]Ozalevli S, Ucan ES: The comparison of different dyspnoea scales in patients with COPD. J Eval Clin Pract 2006, 12(5):532-538.
• [22]Wijkstra PJ, TenVergert EM, van der Mark TW, Postma DS, Van Altena R, Kraan J, Koeter GH: Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. Thorax 1994, 49(5):468-472.
• [23]Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A: Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002, 39(2):202-209.
• [24]Pesola GR: The use of B-type natriuretic peptide (BNP) to distinguish heart failure from lung disease in patients presenting with dyspnea to the emergency department. Acad Emerg Med 2003, 10(3):275-277.